Kaynasli

Researchers are evaluating the efficacy and safety of two different dose regimens of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stage F2 or F3. This Phase 3 study aims to better understand how pegozafermin may impact liver fibrosis and steatohepatitis in this population. Participants will receive subcutaneous injections of either one of two pegozafermin regimens or a matched placebo. These treatments are given in parallel groups, and participants are randomly assigned to one of the study groups. The study compares the effects of pegozafermin on liver fibrosis and steatohepatitis over a treatment period that includes evaluations up to 52 weeks and monitoring for disease progression up to 5 years. During the study, participants will be monitored through biopsies and blood tests to assess liver fibrosis improvement, resolution of steatohepatitis, changes in liver enzyme levels, and enhanced liver fibrosis scores. Safety and disease progression are also tracked throughout the study period. The total participation duration includes treatment and long-term observation to evaluate outcomes and any potential changes in liver health.

Chronic low back pain is common in older adults and is linked to problems with balance, higher chances of falling, frailty, depression, and reduced physical ability. Researchers are studying how different ways of focusing attention during virtual reality-based exercise might affect these issues. This trial compares the effects of focusing attention externally versus internally during a core stabilization exercise program in older adults with chronic low back pain. Participants will be randomly assigned to two groups one receiving verbal and visual cues to focus on movement effects on the environment external focus, and the other focusing on body movements and muscle control internal focus. Both groups will perform the same virtual reality-assisted core stabilization exercises three times a week for six weeks, with sessions lasting 45 to 60 minutes under physiotherapist supervision in a safe clinical setting. Participants will be assessed before and after the six-week program using measures such as frailty level, balance and fall risk, lower limb strength, sarcopenia risk, and depression symptoms. Tests include the Frailty Assessment Scale, Biodex Balance System, Five Times Sit-to-Stand Test, SARC-T questionnaire, and Beck Depression Inventory. Researchers aim to find out if the different focus strategies lead to different physical, functional, and psychological outcomes in these older adults.

Researchers are conducting an observational study to screen adults aged 18 and over who visit hospital outpatient clinics in Turkey for malnutrition and sarcopenia risks. The study focuses on patients attending oncology, neurology, and geriatric clinics to better understand these conditions across diverse patient groups. This non-interventional, cross-sectional design means participants are observed without receiving experimental treatments. Participants are screened once during their outpatient visit without any study treatments or interventions. The study collects information on malnutrition risk, sarcopenia risk, body mass index, calf circumference, hand grip strength, biochemical parameters, healthcare use, and nutrition treatments. Data is gathered on the screening day only. During the study visit, researchers will assess physical and biochemical measures to evaluate nutrition and muscle health. Participants provide informed consent before any assessments. The study measures malnutrition and sarcopenia risks as primary outcomes on the first day and includes several secondary measures related to body composition and healthcare use. The study will continue enrolling participants until April 2027.

Researchers are evaluating the safety and tolerability of tarperprumig in adults diagnosed with or experiencing a relapse of anti-neutrophil cytoplasmic antibody ANCA-associated vasculitis, specifically targeting granulomatosis with polyangiitis GPA and microscopic polyangiitis MPA subtypes. This phase 2 study aims to explore tarperprumigs effects compared to placebo in participants considered for treatment with rituximab or cyclophosphamide. Participants will be randomized to receive one of two dose regimens of tarperprumig or a placebo in a double-blind, parallel-group design. The treatment period lasts up to 70 weeks, during which participants receive their assigned study drug. The study uses a quadruple masking approach to ensure unbiased results and compares safety, tolerability, and efficacy outcomes among groups. Throughout the study, participants will undergo regular assessments including monitoring for treatment-emergent adverse events, evaluations of disease remission status, and measurements of disease activity using the Birmingham Vasculitis Activity Score BVAS. Additional tests include kidney function assessments and proteinuria measurements at baseline and at scheduled weeks. Safety and disease progression will be closely followed up to week 70, with comprehensive data collection on vasculitis damage and relapse occurrences.

Researchers are evaluating the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients who have chronic heart failure, impaired kidney function, and have recently experienced a heart failure event. This Phase III study is conducted internationally across about 700 sites and aims to assess how these treatments impact cardiovascular death and heart failure events. Participants will be randomly assigned to one of three groups balcinrenonedapagliflozin 15 mg10 mg plus placebo, balcinrenonedapagliflozin 40 mg10 mg plus placebo, or dapagliflozin 10 mg plus placebo. Each participant will take one capsule and one tablet daily. The study duration averages 22 months, including screening, about 20 months of blinded treatment, and a one-month follow-up with open-label dapagliflozin. During the study, participants will undergo assessments for heart failure events, hospitalizations, and cardiovascular death. Researchers will monitor these outcomes over about 38 months, including symptom scores and other health measures. Safety and treatment effects will be followed during the treatment and the one-month post-treatment period.

Researchers are studying the effects of different kinesiology taping techniques on the thickness of the thoracolumbar fascia, pain levels, and functional disability in people with nonspecific chronic low back pain. This randomized controlled trial will include 30 adults aged 18 to 65 years who have been diagnosed with nonspecific mechanical chronic low back pain. The study aims to provide evidence-based data on how these taping methods may impact the fascia and symptoms in this condition. Participants will be randomly assigned to one of three groups the Functional Fascial Taping Group will receive kinesiology tape applied with a fascia correction technique using I and Y strips with 10-50% oscillatory tension the Muscle Technique Taping Group will receive traditional muscle taping on paravertebral muscles with varying tension levels and the Damascus Taping Group will receive sham taping without therapeutic tension or targeted correction. All taping interventions will be applied twice a week for two weeks. In addition, all participants will perform cervical stabilization exercises over six weeks. Participants will be evaluated before and after treatment for pain intensity using the Visual Analog Scale, pressure pain threshold with an algometer, functional disability using the Oswestry Low Back Pain Disability Index, and fascia thickness using ultrasound imaging. Secondary assessments include posture, spinal mobility, and endurance tests. The study will monitor changes over six weeks to assess the impact of the different taping techniques on clinical and tissue-level outcomes.

Osteoporosis is a progressive disease that leads to reduced bone mass, weaker bone structure, and increased risk of fractures. Postmenopausal women are especially at risk, with over 80% affected after age 50 and nearly all individuals over 75 showing signs. This study aims to explore how virtual reality applications might improve balance, quality of life, and reduce fall risk in postmenopausal women with osteoporosis, comparing these effects to a control group receiving traditional treatment. Participants will be randomly assigned to one of two groups. The control group will receive traditional treatment including posture, strengthening, and balance exercises patient education to prevent falls and fractures aerobic exercises and pain management strategies. The virtual reality group will engage with video-based games and videos designed as exergames to encourage physical activity and balance training. The study will carefully monitor for any adverse effects from the virtual reality program and adjust it if necessary. During the 6-week study, participants will be assessed for balance, cognitive state, and risk of falling. Quality of life will also be measured as a secondary outcome. Assessments will involve physical evaluations and cognitive tests to track progress. Participants must be postmenopausal women aged 50 to 75 with osteoporosis confirmed by bone density testing, and able to walk independently. The study aims to provide new insights into the use of virtual reality as a therapeutic tool for osteoporosis-related challenges.